{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:00:57Z","timestamp":1787508057016,"version":"build-2736575974"},"reference-count":37,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                    <jats:label\/>\n                    <jats:p>\n                      <jats:bold>Aims:<\/jats:bold>\n                      Guselkumab, a monoclonal antibody that binds to the p19 subunit of interleukin 23, is approved for the treatment of plaque psoriasis (PsO) and psoriatic arthritis (PsA), palmoplantar pustulosis (PPP), generalized pustular psoriasis, and erythrodermic psoriasis in various countries. The purpose of this analysis was to develop a comprehensive population pharmacokinetic (PK) model for guselkumab to determine whether PK differs across different disease populations and healthy subjects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A nonlinear mixed\u2010effects modelling approach was used to analyse 23\u2009097 serum PK samples obtained from 2623 healthy subjects and patients with PsO, PsA and PPP across 9 phase 1\u20133 clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Guselkumab concentrations were adequately described by a 2\u2010compartment linear PK model with first\u2010order absorption and elimination. Clearance (CL), central and peripheral volume of distribution, intercompartmental flow, absorption rate constant and absolute bioavailability estimates were 0.255\u2009L\/d, 3.60\u2009L, 1.78\u2009L, 0.369\u2009L\/d, 0.313\u2009d\n                      <jats:sup>\u22121<\/jats:sup>\n                      and 49.2%, respectively, for a subject weighing 70\u2009kg. Terminal half\u2010life was estimated to be approximately 14.6\u00a0days. Body weight was the primary factor affecting CL and central volume of distribution. CL of guselkumab was similar among patients with PsA, PsO and PPP, but CL in disease populations was 11\u201317% lower than that in healthy subjects after other covariate effects such as body weight were considered.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The population pharmacokinetic analysis indicated that, after other covariate effects were taken into account, patients with PsO, PsA and PPP had similar PK characteristics, with CL in these disease populations being slightly lower than in healthy individuals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bcp.15364","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T20:18:35Z","timestamp":1650917915000},"page":"4481-4493","source":"Crossref","is-referenced-by-count":15,"title":["Population pharmacokinetics analysis of guselkumab in healthy subjects and patients with psoriatic arthritis, plaque psoriasis and palmoplantar pustulosis"],"prefix":"10.1111","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9696-3164","authenticated-orcid":false,"given":"Lana","family":"Tran","sequence":"first","affiliation":[{"name":"Clinical Pharmacology and Pharmacometrics Janssen Research &amp; Development, LLC  Spring House PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenling","family":"Yao","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Pharmacometrics Janssen Research &amp; Development, LLC  Spring House PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Xu","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Pharmacometrics Janssen Research &amp; Development, LLC  Spring House PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Vermeulen","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Pharmacometrics Janssen Research &amp; Development, a division of Janssen Pharmaceutica NV  Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,5,13]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1063"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0900036"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1000600"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3895"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.146"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2008.03.004"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/441166a"},{"key":"e_1_2_10_9_1","volume-title":"FDA Approval of Tremfya\u2122 (Guselkumab) for the Treatment of Moderate to Severe Plaque Psoriasis","author":"Janssen Announces U.S"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501646"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.041"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.042"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(18)30952\u20108"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(20)30265\u20108"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(20)30263\u20104"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.5937"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.1394"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0009\u20108981(81)90005\u2010X"},{"key":"e_1_2_10_19_1","series-title":"Wiley series in probability and mathematical statistics Applied probability and statistics","first-page":"504","volume-title":"Introduction to linear regression analysis","author":"Montgomery DC","year":"1982"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011527125570"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjem.2018.08.001"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1582"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1101"},{"key":"e_1_2_10_24_1","unstructured":"Administration U.S.D.o.H.a.H.S.F.a.D. Statistical Approaches to Establishing Bioequivalence C.f.D.E.a. Research Editor2001."},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928\u2010017\u20109531\u20103"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012299115260"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010016\u20102110\u20105"},{"key":"e_1_2_10_28_1","unstructured":"Guselkumab Multi\u2010Discipline Review\/Summary Clinical Non\u2010Clinical. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/761061Orig1s000MultidisciplineR.pdf"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.2165\/11535960\u2010000000000\u201000000"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010018\u20100704\u2010z"},{"key":"e_1_2_10_31_1","unstructured":"FDA.Multi\u2010discipline review of guselkumab BLA 761061. April 11 2022]; Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/761061Orig1s000MultidisciplineR.pdf"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12136"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.2165\/11599820\u2010000000000\u201000000"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12355"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010017\u20100586\u20105"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102249.1993.tb08216.x"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.500"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00271683"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15364","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.15364","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15364","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T12:46:48Z","timestamp":1692794808000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.15364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,13]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1111\/bcp.15364"],"URL":"https:\/\/doi.org\/10.1111\/bcp.15364","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,13]]}}}